Cargando…
Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects
Early diagnosis and treatment of rheumatoid arthritis (RA) are of critical importance to halt the progression of the disease. Optimal use of advanced imaging techniques or biomarkers may facilitate early diagnosis of RA. Even though many disease-modifying anti-rheumatic drugs (DMARDs) are available...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186742/ https://www.ncbi.nlm.nih.gov/pubmed/34099538 http://dx.doi.org/10.1136/rmdopen-2021-001637 |
_version_ | 1783705007108915200 |
---|---|
author | Smolen, Josef S Caporali, Roberto Doerner, Thomas Fautrel, Bruno Benedetti, Fabrizio Pieper, Burkhard Jang, Minjun |
author_facet | Smolen, Josef S Caporali, Roberto Doerner, Thomas Fautrel, Bruno Benedetti, Fabrizio Pieper, Burkhard Jang, Minjun |
author_sort | Smolen, Josef S |
collection | PubMed |
description | Early diagnosis and treatment of rheumatoid arthritis (RA) are of critical importance to halt the progression of the disease. Optimal use of advanced imaging techniques or biomarkers may facilitate early diagnosis of RA. Even though many disease-modifying anti-rheumatic drugs (DMARDs) are available for RA treatment, biological DMARDs (bDMARDs) offer expanding therapeutic options and good outcomes in patients with RA who do not have a sufficient response to conventional synthetic DMARDs. However, high costs of bDMARDs have limited patient access to optimised disease management and increased the cost burden for healthcare systems. The advent of biosimilars led to significant cost savings driven by price competition among the reference products, which could be beneficial for healthcare systems. Healthcare provider (HCP)–patient communication and informed shared decision-making are crucial to prevent the occurrence of a nocebo effect, which results from negative perceptions that patients may have and could lead to less effective outcomes. Research has demonstrated that effective communication between HCPs and patients utilising positive framing can improve acceptance by patients to be initiated on or switched to a biosimilar and can help to integrate biosimilars into routine clinical practice to maximise benefits for patients with RA. |
format | Online Article Text |
id | pubmed-8186742 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-81867422021-06-25 Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects Smolen, Josef S Caporali, Roberto Doerner, Thomas Fautrel, Bruno Benedetti, Fabrizio Pieper, Burkhard Jang, Minjun RMD Open Rheumatoid Arthritis Early diagnosis and treatment of rheumatoid arthritis (RA) are of critical importance to halt the progression of the disease. Optimal use of advanced imaging techniques or biomarkers may facilitate early diagnosis of RA. Even though many disease-modifying anti-rheumatic drugs (DMARDs) are available for RA treatment, biological DMARDs (bDMARDs) offer expanding therapeutic options and good outcomes in patients with RA who do not have a sufficient response to conventional synthetic DMARDs. However, high costs of bDMARDs have limited patient access to optimised disease management and increased the cost burden for healthcare systems. The advent of biosimilars led to significant cost savings driven by price competition among the reference products, which could be beneficial for healthcare systems. Healthcare provider (HCP)–patient communication and informed shared decision-making are crucial to prevent the occurrence of a nocebo effect, which results from negative perceptions that patients may have and could lead to less effective outcomes. Research has demonstrated that effective communication between HCPs and patients utilising positive framing can improve acceptance by patients to be initiated on or switched to a biosimilar and can help to integrate biosimilars into routine clinical practice to maximise benefits for patients with RA. BMJ Publishing Group 2021-06-07 /pmc/articles/PMC8186742/ /pubmed/34099538 http://dx.doi.org/10.1136/rmdopen-2021-001637 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Rheumatoid Arthritis Smolen, Josef S Caporali, Roberto Doerner, Thomas Fautrel, Bruno Benedetti, Fabrizio Pieper, Burkhard Jang, Minjun Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects |
title | Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects |
title_full | Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects |
title_fullStr | Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects |
title_full_unstemmed | Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects |
title_short | Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects |
title_sort | treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects |
topic | Rheumatoid Arthritis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186742/ https://www.ncbi.nlm.nih.gov/pubmed/34099538 http://dx.doi.org/10.1136/rmdopen-2021-001637 |
work_keys_str_mv | AT smolenjosefs treatmentjourneyinrheumatoidarthritiswithbiosimilarsfrombetteraccesstogooddiseasecontrolthroughcostsavingsandpreventionofnoceboeffects AT caporaliroberto treatmentjourneyinrheumatoidarthritiswithbiosimilarsfrombetteraccesstogooddiseasecontrolthroughcostsavingsandpreventionofnoceboeffects AT doernerthomas treatmentjourneyinrheumatoidarthritiswithbiosimilarsfrombetteraccesstogooddiseasecontrolthroughcostsavingsandpreventionofnoceboeffects AT fautrelbruno treatmentjourneyinrheumatoidarthritiswithbiosimilarsfrombetteraccesstogooddiseasecontrolthroughcostsavingsandpreventionofnoceboeffects AT benedettifabrizio treatmentjourneyinrheumatoidarthritiswithbiosimilarsfrombetteraccesstogooddiseasecontrolthroughcostsavingsandpreventionofnoceboeffects AT pieperburkhard treatmentjourneyinrheumatoidarthritiswithbiosimilarsfrombetteraccesstogooddiseasecontrolthroughcostsavingsandpreventionofnoceboeffects AT jangminjun treatmentjourneyinrheumatoidarthritiswithbiosimilarsfrombetteraccesstogooddiseasecontrolthroughcostsavingsandpreventionofnoceboeffects |